Castration-Refractory Prostate Cancer: New Drugs in the Pipeline

被引：13
|
作者：
Schrijvers, Dirk [1 ]
Van Erps, Peter [2 ]
Cortvriend, Jim [2 ]
机构：
[1] Ziekenhuisnetwerk Antwerpen Middelheim, Dept Hematooncol, B-2020 Antwerp, Belgium
[2] Ziekenhuisnetwerk Antwerpen Middelheim, Dept Urol, B-2020 Antwerp, Belgium
来源：
ADVANCES IN THERAPY | 2010年 / 27卷 / 05期
关键词：
castration-refractory prostate cancer; docetaxel; cabazitaxel; abiraterone acetate; angiogenesis modulators; vaccines; PHASE-II TRIAL; ABIRATERONE ACETATE; 2ND-LINE CHEMOTHERAPY; PLUS PREDNISONE; CLINICAL-TRIAL; DOCETAXEL; INHIBITOR; CYP17; MITOXANTRONE; THALIDOMIDE;
D O I：
10.1007/s12325-010-0038-1
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The standard treatment for patients with castration-refractory prostate cancer (CRPC) is the combination docetaxel-prednisone, if the patient can support chemotherapy. Several new treatments have been tested in chemotherapy-naive or docetaxel-pretreated patients with CRPC. Some of these treatments have shown activity in first-line and second-line treatment. In this review, an update is given of new treatment studies performed in patients with CRPC.
引用
收藏
页码：285 / 296
页数：12
相关论文
共 50 条
  • [11] Report on an International Conference on the diagnosis and treatment of castration-refractory prostate cancer
    Nyushko, K. M.
    ONKOUROLOGIYA, 2014, 10 (01): : 91 - 93
  • [12] Radium-223 dichloride in patients with castration-refractory prostate cancer
    Winter, B. M.
    von Rundstedt, F. -C.
    Grimm, M. -O.
    UROLOGE, 2017, 56 (11): : 1435 - 1439
  • [13] Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer
    Berghen, Charlien
    Joniau, Steven
    Ost, Piet
    Poels, Kenneth
    Everaerts, Wouter
    Decaestecker, Karel
    Haustermans, Karin
    Devos, Gaetan
    De Meerleer, Gert
    EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (02): : 305 - 309
  • [14] A new approach to delay the development of resistance to docetaxel in the treatment of castration-refractory prostate cancer.
    Filleur, S.
    Sennoune, S. R.
    Lees, J. C.
    Hirsch, J.
    Bermudez, L.
    Martinez-Zaguilan, R.
    Nelius, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [15] Making it Less Taxing: Reduced Dose Cabazitaxel in Castration-refractory Prostate Cancer
    Silverman, R.
    Taylor, S.
    Walker, G.
    Sundar, S.
    CLINICAL ONCOLOGY, 2017, 29 (06) : 394 - 395
  • [16] Pain predicts overall survival in men with metastatic castration-refractory prostate cancer
    Halabi, Susan
    Vogelzang, Nicholas J.
    Kornblith, Alice B.
    Ou, San-San
    Kantoff, Philip W.
    Dawson, Nancy A.
    Small, Eric J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) : 2544 - 2549
  • [17] Skeletal events unrelated to bone metastasis in men with castration-refractory prostate cancer
    Kamoi, Kazumi
    Okihara, Koji
    Takaha, Natsuki
    Iwata, Tsuyoshi
    Kawauchi, Akihiro
    Miki, Tsuneharu
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [18] Third-line Therapy for Patients with metastatic castration-refractory Prostate Cancer (mCRPC)
    Rexer, H.
    Hammerer, P.
    Merseburger, A.
    AKTUELLE UROLOGIE, 2019, 50 (02) : 144 - 145
  • [19] Use of radiographic progression to predict overall survival in men with castration-refractory prostate cancer
    Kamoi, Kazumi
    Okihara, Koji
    Takaha, Natsuki
    Iwata, Tsuyoshi
    Kawauchi, Akihiro
    Miki, Tsuneharu
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [20] Current possibilities of treatment for visceral metastases in patients with metastatic castration-refractory prostate cancer
    Govorov, A. V.
    Moiseenko, T. N.
    ONKOUROLOGIYA, 2013, 9 (02): : 53 - 56
12345